KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Raw Materials: 2009-2024

Historic Raw Materials for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $5.6 million.

  • Ionis Pharmaceuticals' Raw Materials fell 97.34% to $640,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $640,000, marking a year-over-year decrease of 97.34%. This contributed to the annual value of $5.6 million for FY2024, which is 207.02% up from last year.
  • As of FY2024, Ionis Pharmaceuticals' Raw Materials stood at $5.6 million, which was up 207.02% from $1.8 million recorded in FY2023.
  • Ionis Pharmaceuticals' Raw Materials' 5-year high stood at $19.8 million during FY2022, with a 5-year trough of $1.8 million in FY2023.
  • Over the past 3 years, Ionis Pharmaceuticals' median Raw Materials value was $5.6 million (recorded in 2024), while the average stood at $9.0 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Raw Materials tumbled by 90.84% in 2023 and then skyrocketed by 207.02% in 2024.
  • Ionis Pharmaceuticals' Raw Materials (Yearly) stood at $16.7 million in 2020, then increased by 11.60% to $18.6 million in 2021, then rose by 5.97% to $19.8 million in 2022, then plummeted by 90.84% to $1.8 million in 2023, then soared by 207.02% to $5.6 million in 2024.